Trials | Patients | Regimen | pCR |
|---|
| | | Tumor | cLN+ | | Breast + LN | Breast |
|---|
| | Stage | >4 cm | (%) | | +CIS*
| –CIS**
| +CIS | –CIS |
|---|
This study | T1-4c, N1-3 | 45% | 100% | AC→SD | 22.5% | NA | 30.6% | 22.5% |
NSAPB B-27 [3] | T1c-3, N0-1 | 45% | 30% | AC | 11.5% | NA | 13.7% | 9.6% |
| | | 45% | 30% | AC→D | 21.8% | NA | 26.1% | 18.9% |
GEPARDUO [13] | T2-3, N0-2 | 32% | 38% | AD | NA | 7.0% | 11.0% | 7.0% |
| | | 33% | 42% | AC→D | NA | 14.3% | 22.3% | 15.9% |
-
A, doxorubicin; C, cyclophosphamide; CIS, carcinoma in situ; cLN, clinically detected lymph node; D, docetaxel; NA, non-assessable; S, S-1. ‘* + CIS’ or ‘**–CIS’ indicates that the definition of pCR includes or does not include CIS.
